IC
JAZZ icon

Inscription Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Inscription Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Sell
1,185
-68
-5% -$14.9K 0.03% 562
2026
Q1 		$237K Buy
1,253
+30
+2% +$5.24K 0.02% 560
2025
Q4 		$208K Buy
+1,223
New +$187K 0.02% 604
2019
Q2 		– Sell
-142
Closed -$20K – 182
2019
Q1 		$20K Sell
142
-310
-69% -$40.4K 0.01% 221
2018
Q4 		$56K Buy
+452
New +$67.1K 0.03% 190

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Inscription Capital's JAZZ Position: Q2 2026 in Review

Inscription Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 5.4% in Q2 2026, selling an estimated $14.9K and leaving 1,185 shares worth $286K. The position accounts for 0.03% of the portfolio, ranked #562.

Inscription Capital first reported a position in JAZZ in Q4 2018 and has held it in 5 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Inscription Capital held 1,185 shares of Jazz Pharmaceuticals worth $286K as of Q2 2026.
  • Inscription Capital sold 68 Jazz Pharmaceuticals shares in Q2 2026, an estimated $14.9K.
  • Jazz Pharmaceuticals made up 0.03% of Inscription Capital's portfolio in Q2 2026, its #562 holding.
  • Inscription Capital first reported a position in Jazz Pharmaceuticals in Q4 2018 and has held it in 5 quarters since.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.